Monday, August 4, 2014
Macrocycle therapies can block protein-protein interactions that are
undruggable with small molecules; however, oral availability and cell
penetration remain key challenges. Encycle
Therapeutics Inc.'s chemistry platform generates drug-like
macrocycles against validated targets to treat diseases for which oral
therapies are needed.
inhibitors of protein-protein interactions include
biologics and other molecules large enough to target the wide, shallow surfaces
involved in those interactions, but can only bind extracellular targets.
Macrocycles can have sufficient size to block protein-protein interactions yet
remain small enough to penetrate cells and block intracellular interactions
that biologics and small molecules cannot.